Freeline Therapeutics Holdings PLC
NASDAQ:FRLN
Intrinsic Value
Freeline Therapeutics Holdings Plc operates as holding company whose subsidiaries provide biotechnology services. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of FRLN.
Freeline Therapeutics Holdings PLC's market capitalization is 28.2m USD.
FRLN stock price is 6.48 USD.
FRLN.
FRLN. Open DCF Valuation
FRLN. Open Relative Valuation
FRLN has upside potential of 27% compared to the average analyst price target.
Open Wall St Estimates
FRLN's short-term assets (34m USD) exceed its short-term liabilties (17m USD).
FRLN has negative Operating Income for the last twelve months.
FRLN has negative Net Income for the last twelve months.
FRLN's ROE (Return on Equity) for the past 12 months is negative and is equal to -101%.
FRLN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -374%.
FRLN's long-term assets (49m USD) exceed its long-term liabilties (19m USD).
FRLN has negative Free Cash Flow for the last twelve months.
FRLN has negative three-year average ROE (Return on Equity): -91%. The company is not efficient at transforming stockholders' equity into net income.
FRLN has negative three-year average ROIC (Return on Invested Capital): -362%. The company is not efficient at using invested capital to generate operating income.
FRLN's D/E (Debt to Equity) is very low and is equal to 0.
FRLN's Altman Z-Score is very low and is equal to -17.65.
Fundamental Analysis
Freeline Therapeutics Holdings PLC
Balance Sheet Decomposition
Freeline Therapeutics Holdings PLC
| Current Assets | 34m |
| Cash & Short-Term Investments | 29.5m |
| Receivables | 1.8m |
| Other Current Assets | 2.7m |
| Non-Current Assets | 15.2m |
| PP&E | 12.6m |
| Other Non-Current Assets | 2.7m |
| Current Liabilities | 17.5m |
| Accounts Payable | 7.8m |
| Accrued Liabilities | 9.4m |
| Other Current Liabilities | 283k |
| Non-Current Liabilities | 1.7m |
| Other Non-Current Liabilities | 1.7m |
Earnings Waterfall
Freeline Therapeutics Holdings PLC
|
Revenue
|
625k
USD
|
|
Operating Expenses
|
-67.8m
USD
|
|
Operating Income
|
-67.2m
USD
|
|
Other Expenses
|
17.2m
USD
|
|
Net Income
|
-49.9m
USD
|
Free Cash Flow Analysis
Freeline Therapeutics Holdings PLC
FRLN Profitability Score
Profitability Due Diligence
Freeline Therapeutics Holdings PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Freeline Therapeutics Holdings PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
FRLN Solvency Score
Solvency Due Diligence
Freeline Therapeutics Holdings PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Freeline Therapeutics Holdings PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FRLN Price Targets Summary
Freeline Therapeutics Holdings PLC
According to Wall Street analysts, the average 1-year price target for
FRLN
is 8.25 USD
.
Shareholder Return
FRLN Price
Freeline Therapeutics Holdings PLC
| Average Annual Return | -54.6% |
| Standard Deviation of Annual Returns | 47.05% |
| Max Drawdown | -99% |
| Market Capitalization | 28.2m USD |
| Shares Outstanding | 4 357 950 |
| Percentage of Shares Shorted | 0.61% |
Company Profile
Freeline Therapeutics Holdings PLC
Country
Industry
Market Cap
Dividend Yield
Description
Freeline Therapeutics Holdings Plc operates as holding company whose subsidiaries provide biotechnology services. The company is headquartered in Stevenage, Hertfordshire and currently employs 235 full-time employees. The company went IPO on 2020-08-07. The firm's initial focus is on developing treatments for monogenic diseases. The firm focuses to deliver one-time gene therapy treatments that provides functional cures through permanently sustained physiological protein levels, leveraging the expression enabled by its gene therapy platform. The firm's AAV vector technology cassette is designed to deliver a functional copy of a therapeutic gene into the human liver to offer secretion of the therapeutic proteins into the patient's blood. Its pipeline consists of four gene therapy product candidates. Its lead product candidate, FLT180a, is for the treatment of hemophilia B. Its second product candidate, FLT190, is for the treatment of Fabry disease. Its third and fourth product candidates are FLT201, for the treatment of Gaucher disease Type 1 and FLT210, for the treatment of hemophilia A.
You don't have any saved screeners yet
